Skip to content
ADVERTISEMENT

Employers rethink health plans as demand for weight-loss drugs grows – Howden

The data highlighted a growing disconnect between employee expectations and employer affordability.

ADVERTISEMENT

Employers are being forced to reassess workplace health benefits as demand for weight-management drugs rises sharply, according to findings from Howden’s Global Employee Health Report 2026.

The data highlighted a growing disconnect between employee expectations and employer affordability.

More than a quarter of UK employees said they have already used a weight-management drug, while two fifths believe these treatments should be included as part of workplace health benefits.

The report showed that 93% of organisations expect global medical costs to increase, with medical inflation forecast to reach 7% in 2026.

When combined with broader inflation, employers are facing total cost increases of over 10% in the year ahead.

ADVERTISEMENT

As a result, nearly half of employers are reassessing their healthcare plans, with a significant proportion shifting focus toward preventative care.

Many organisations are investing more in early intervention strategies to manage long-term costs, positioning weight-management treatments as part of a broader prevention approach rather than a standalone benefit.

Cheryl Brennan, managing director of Howden Employee Benefits, said: “The demand for these drugs is obvious, and employers can simply not afford to ignore it.

ADVERTISEMENT

“However, the financial impact of new obesity medications also cannot be overlooked. It is no longer a future projection – it’s a current reality that is forcing business leaders to rethink their plan design and budget allocations.”

Brennan added: “Costs are rising rapidly and medical inflation is set to be 7%, meaning when combined with general inflation, businesses are facing combined price hikes of over 10% over the next year.

ADVERTISEMENT

“As a result, the focus of healthcare is changing to preventative measures, in an attempt to mitigate the effects of costs as early as possible, and weight-management drugs are becoming more popular as a prevention tool.

ADVERTISEMENT

“Treading the line on which drugs to cover will be weighing on the minds of business leaders. There remains plenty of drugs and treatments which are currently not covered by employers’ health plans. So firms will need to justify why they chose to cover weight loss drugs ahead of others.

“And with demand soaring, consideration must be given to the guardrails in place surrounding eligibility.

“Businesses will have to work out if this improvement balances the scales enough to absorb the cost and cover these drugs as part of their healthcare plans, which has the potential to reshape the employee healthcare space dramatically over the coming years.”